Investment firms seek to provide a strong return for their investors in various areas — from stocks, bonds, equity investments in companies and real estate. But what happens when a hedge fund, for instance, underwrites mass tort litigation against a life sciences company with FDA-approved products on the market and in the pipeline? If the […]
Author Archives: Pat Fogarty
Pat Fogarty is the deputy general counsel and Senior Vice President of
Legal at the Advanced Medical Technology Association (AdvaMed). He wrote this for InsideSources.com